Daniel N. Swisher, Jr
2011 - Sunesis Pharmaceuticals
In 2011, Daniel N. Swisher, Jr earned a total compensation of $1.7M as CEO and President at Sunesis Pharmaceuticals, a 165% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $191,900 |
|---|---|
| Option Awards | $1,090,350 |
| Salary | $417,150 |
| Other | $3,130 |
| Total | $1,702,530 |
Swisher received $1.1M in option awards, accounting for 64% of the total pay in 2011.
Swisher also received $191.9K in non-equity incentive plan, $417.2K in salary and $3.1K in other compensation.
Rankings
In 2011, Daniel N. Swisher, Jr's compensation ranked 3,799th out of 10,747 executives tracked by ExecPay. In other words, Swisher earned more than 64.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,799 out of 10,747 | 65th |
Division Manufacturing | 1,334 out of 3,960 | 66th |
Major group Chemicals And Allied Products | 266 out of 1,033 | 74th |
Industry group Drugs | 153 out of 781 | 80th |
Industry Pharmaceutical Preparations | 125 out of 571 | 78th |
Source: SEC filing on April 25, 2013.
Swisher's colleagues
We found two more compensation records of executives who worked with Daniel N. Swisher, Jr at Sunesis Pharmaceuticals in 2011.
News
Jazz Pharmaceuticals CEO Bruce Cozadd's 2021 pay jumps 25% to $16M
June 10, 2022
Jazz Pharmaceuticals CEO Bruce Cozadd's 2020 pay slips 15% to $13M
June 11, 2021
Jazz Pharmaceuticals CEO Bruce Cozadd's 2019 pay jumps 29% to $15M
June 12, 2020
Jazz Pharmaceuticals CEO Bruce Cozadd's 2018 pay rises 11% to $11M
June 14, 2019